CoChat
Sign Up
Cited by 62Diabetes Management and ResearchProtein purification and stabilityAdvanced Drug Delivery Systems

An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients

Open access
Mann, Joseph L., Maikawa, Caitlin L., Smith, Anton A. A., Grosskopf, Abigail K., Baker, Sam W., Roth, Gillie A., Meis, Catherine M., Gale, Emily C. +9 more·2020·Science Translational Medicine
DOI 10.1126/scitranslmed.aba6676PMC PMC7716884
Open this paper in CoChat — free accountOpen PDF

Abstract

Monomeric insulin stabilized with polymeric excipient exhibits increased stability and faster pharmacokinetics than current rapid-acting insulins.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aba6676

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Additional novel formulations are being investigated in animal studies.

    “and additional novel formulations are being investigated in animal studies.83”

    From The future of type 1 diabetes therapy (2025) · cites this paper as [83]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 50 · Cited by 62

Research works printed but not linked: 46

  1. [3]Polonsky KS, Given BD, Van Cauter E, Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects, J. Clin. Invest 81, 442– 448 (1988). 3276730 PMC329589
  2. [4]Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW, The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes, Diabetes 54, 1100– 1107 (2005). 15793249
  3. [5]Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H, Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial, Diabetes Obes. Metab 19, 208– 215 (2017). 27709762 PMC5299522
  4. [6]Senior P, Hramiak I, {Fast-Acting} Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective, Can J Diabetes 43, 515– 523 (2019). 30872107
  5. [7]Holleman F, Hoekstra JB, Insulin lispro N Engl. J. Med 337, 176– 183 (1997). 9219705
  6. [8]Gast K, Schüler A, Wolff M, Thalhammer A, Berchtold H, Nagel N, Lenherr G, Hauck G, Seckler R, {Rapid-Acting} and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation, Pharm. Res 34, 2270– 2286 (2017). 28762200 PMC5643355
  7. [9]Mathieu C, Gillard P, Benhalima K, Insulin analogues in type 1 diabetes mellitus: getting better all the time, Nat. Rev. Endocrinol 13, 385– 399 (2017). 28429780
  8. [10]Gingras V, Taleb N, Roy-Fleming A, Legault L, Rabasa-Lhoret R, The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes, Diabetes Obes. Metab 20, 245– 256 (2018). 28675686 PMC5810921
  9. [11]Cengiz E, Undeniable need for ultrafast-acting insulin: the pediatric perspective, J. Diabetes Sci. Technol 6, 797– 801 (2012). 22920804 PMC3440149
  10. [12]Hua Q-X, Weiss MA, Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate, J. Biol. Chem 279, 21449– 21460 (2004). 14988398
  11. [13]Woods RJ, Alarcón J, McVey E, Pettis RJ, Intrinsic fibrillation of fast-acting insulin analogs, J. Diabetes Sci. Technol 6, 265– 276 (2012). 22538135 PMC3380767
  12. [14]Xu Y, Yan Y, Seeman D, Sun L, Dubin PL, Multimerization and aggregation of native-state insulin: effect of zinc, Langmuir 28, 579– 586 (2012). 22059434
  13. [15]Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, Sparks C, Swenson D, Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer, Nature 338, 594– 596 (1989). 2648161
  14. [16]Weiss MA, in Vitamins & Hormones, (Academic Press, 2009), vol. 80, pp. 33– 49. 19251033 PMC3297421
  15. [17]Sluzky V, Tamada JA, Klibanov AM, Langer R, Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces, Proc. Natl. Acad. Sci. U. S. A 88, 9377– 9381 (1991). 1946348 PMC52720
  16. [18]Sluzky V, Klibanov AM, Langer R, Mechanism of insulin aggregation and stabilization in agitated aqueous solutions, Biotechnol. Bioeng 40, 895– 903 (1992). 18601196
  17. [19]Nault L, Guo P, Jain B, Bréchet Y, Bruckert F, Weidenhaupt M, Human insulin adsorption kinetics, conformational changes and amyloidal aggregate formation on hydrophobic surfaces, Acta Biomater. 9, 5070– 5079 (2013). 23022543
  18. [20]Muzaffar M, Ahmad A, The mechanism of enhanced insulin amyloid fibril formation by {NaCl} is better explained by a conformational change model, PLoS One 6, e27906 (2011). 22132167 PMC3221682
  19. [21]Webber MJ, Appel EA, Vinciguerra B, Cortinas AB, Thapa LS, Jhunjhunwala S, Isaacs L, Langer R, Anderson DG, Supramolecular {PEGylation} of biopharmaceuticals, Proc. Natl. Acad. Sci. U. S. A 113, 14189– 14194 (2016). 27911829 PMC5167179
  20. [22]Yang C, Lu D, Liu Z, How PEGylation enhances the stability and potency of insulin: A molecular dynamics simulation, Biochemistry 50, 2585– 2593 (2011). 21332191
  21. [23]Liu Y, Lee J, Mansfield KM, Ko JH, Sallam S, Wesdemiotis C, Maynard HD, Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein, Bioconjug. Chem 28, 836– 845 (2017). 28044441 PMC5352466
  22. [24]Maikawa CL, Smith AAA, Zou L, Meis CM, Mann JL, Webber MJ, Appel EA, Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues, Adv. Ther. PMC7079736 32190729
  23. [25]Bertrand N, Leroux J-C, The journey of a drug-carrier in the body: An anatomo-physiological perspective, J. Control. Release 161, 152– 163 (2012). 22001607
  24. [26]Ting JM, Tale S, Purchel AA, Jones SD, Widanapathirana L, Tolstyka ZP, Guo L, Guillaudeu SJ, Bates FS, Reineke TM, High-Throughput Excipient Discovery Enables Oral Delivery of Poorly Soluble Pharmaceuticals, ACS Cent. Sci 2, 748– 755 (2016). 27800558 PMC5084074
  25. [27]Amended Final Report on the Safety Assessment of Polyacrylamide and Acrylamide Residues in Cosmetics1, Int. J. Toxicol 24, 21– 50 (2005). 16154914
  26. [28]Patil SM, Keire DA, Chen K, Comparison of {NMR} and Dynamic Light Scattering for Measuring Diffusion Coefficients of Formulated Insulin: Implications for Particle Size Distribution Measurements in Drug Products, AAPS J. 19, 1760– 1766 (2017). 28791599 PMC6058974
  27. [29]Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T, Ultra-rapid {BioChaperone} Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes, Diabetes Obes. Metab 20, 2627– 2632 (2018). 29923294
  28. [30]Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR, A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes, Diabetes Care 25, 2053– 2057 (2002). 12401756
  29. [31]Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H, Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart, Diabetes Obes. Metab 17, 682– 688 (2015). 25846340 PMC5054830
  30. [32]Fath M, Danne T, Biester T, Erichsen L, Kordonouri O, Haahr H, Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus, Pediatr. Diabetes 18, 903– 910 (2017). 28165180
  31. [33]Wong J, Chase JG, Hann CE, Shaw GM, Lotz TF, Lin J, Le Compte AJ, A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Model Structure and Parameter Identification, J. Diabetes Sci. Technol 2, 658– 671 (2008). 19885242 PMC2769764
  32. [34]Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hövelmann U, Kurth H-J, Sutter DE, Harvey NG, Heinemann L, Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes, Diabetes Technol. Ther 13, 443– 450 (2011). 21355716
  33. [35]Rave K, Klein O, Frick AD, Becker RHA, Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes, Diabetes Care 29, 1812– 1817 (2006). 16873785
  34. [36]Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B, {BioChaperone} Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study, Diabetes Obes. Metab (2018). 30565407
  35. [37]Lindholm A, McEwen J, Riis AP, Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes, Diabetes Care 22, 801– 805 (1999). 10332685
  36. [38]Becker RHA, Frick AD, Clinical pharmacokinetics and pharmacodynamics of insulin glulisine, Clin. Pharmacokinet 47, 7– 20 (2008). 18076215
  37. [39]Kavitha A, Parambath A, in Engineering of Biomaterials for Drug Delivery Systems, Parambath A, Ed. (Woodhead Publishing, 2018), pp. 229– 253.
  38. [40]Gorman M, Chim YH, Hart A, Riehle MO, Urquhart AJ, {Poly(N-acryloylmorpholine)}: a simple hydrogel system for temporal and spatial control over cell adhesion, J. Biomed. Mater. Res. A 102, 1809– 1815 (2014). 23784937
  39. [42]Leelarathna L, Ashley D, Fidler C, Parekh W, The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a {UK} health care system perspective, Ther. Adv. Endocrinol. Metab 9, 187– 197 (2018). 29977497 PMC6022975
  40. [43]Haahr H, Pieber TR, Mathieu C, Gondolf T, Shiramoto M, Erichsen L, Heise T, Clinical Pharmacology of {Fast-Acting} Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to {Anti-Insulin} Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus, Clin. Pharmacokinet 58, 639– 649 (2019). 30402720 PMC6451708
  41. [44]Heinemann L, Baughman R, Boss A, Hompesch M, Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin, J. Diabetes Sci. Technol 11, 148– 156 (2017). 27378794 PMC5375067
  42. [45]Larsen MO, Rolin B, Use of the Göttingen minipig as a model of diabetes, with special focus on type 1 diabetes research, ILAR J. 45, 303– 313 (2004). 15229377
  43. [46]Radziuk JM, Davies JC, Pye WS, Shields JE, DiMarchi RD, Chance RE, Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its {analogs--LysB28ProB29-human} insulin and {AspB10LysB28ProB29-human} insulin--assessed in a conscious pig model, Diabetes 46, 548– 556 (1997). 9075793
  44. [47]Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U, Olsen HB, Ludvigsen S, Jeppesen CB, Refsgaard HHF, Bendtsen KM, Kristensen NR, Hostrup S, Sturis J, Elucidating the Mechanism of Absorption of {Fast-Acting} Insulin Aspart: The Role of Niacinamide, Pharm. Res 36, 49 (2019). 30746556 PMC6373292
  45. [49]Jesson CP, Pearce CM, Simon H, Werner A, Cunningham VJ, Lovett JR, Smallridge MJ, Warren NJ, Armes SP, H2O2 Enables Convenient Removal of RAFT End-Groups from Block Copolymer Nano-Objects Prepared via Polymerization-Induced Self-Assembly in Water, Macromolecules 50, 182– 191 (2017). 31007283 PMC6471490
  46. [51]Wu KK, Huan Y, Streptozotocin-induced diabetic models in mice and rats, Curr. Protoc. Pharmacol Chapter 5, Unit 5.47 (2008). 22294227

Authors
Mann, J. L., Maikawa, C. L., Smith, A. A. A., Grosskopf, A. K., Baker, S. W., Roth, G. A., Meis, C. M., Gale, E. C., Liong, C. S., Correa, S., Chan, D., Stapleton, L. M., Yu, A. C., Muir, B., Howard, S., Postma, A., & Appel, E. A.
Affiliations
  • Stanford University (US)
  • Department of Materials Science and Engineering, Stanford University, Stanford, CA 94025, USA.
  • CSIRO Manufacturing, Clayton, VIC 3168, Australia.
  • CSIRO Manufacturing (AU)
Corresponding author
Appel, Eric A.
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2020-07
Volume
12
Issue
550
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.aba6676
PMC
PMC7716884
OpenAlex
W3038606466
Cited by
62
References
50
Citations by year
2026: 7 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 16 · 2021: 14 · 2020: 3
FWCI
7.92
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Defense (NDSEG)
  • Novo Nordisk Fonden (NNF18OC0030896)
  • NIDDK (R01DK119254, P30DK116074)
  • NSERC (Postgraduate Scholarship)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
insulin lispro, insulin aggregation, controlled radical polymerization, high-throughput screening, rapid-acting insulin, pharmacokinetics, postprandial insulin secretion, amyloid fibril formation
MeSH terms
Animals, Blood Glucose, Diabetes Mellitus, Type 2, Excipients, Humans, Hypoglycemic Agents, Insulin, Swine, High-Throughput Screening Assays, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review